# Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

> **NCT00529568** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 759 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** eltrombopag
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00529568
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 759 (ACTUAL)
- **Last updated:** 2013-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529568, "Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00529568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*